Statements (54)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:approves |
gptkb:2009
gptkb:FDA |
| gptkbp:atccode |
C09 AX03
|
| gptkbp:availability |
prescription only
|
| gptkbp:brand |
gptkb:Firazyr
|
| gptkbp:casnumber |
160970-54-8
|
| gptkbp:chemical_formula |
C29 H40 N4 O5 S
|
| gptkbp:class |
bradykinin receptor antagonists
|
| gptkbp:clinical_trial |
Phase III
effective in reducing attack severity studies conducted in multiple countries |
| gptkbp:clinical_use |
self-administration by patients
|
| gptkbp:contraindication |
hypersensitivity to icatibant
|
| gptkbp:dosage_form |
solution for injection
|
| gptkbp:education_requirements |
patient education on self-injection
|
| gptkbp:excretion |
urine
|
| gptkbp:feedback |
generally positive
|
| gptkbp:financial_support |
available from manufacturer
|
| https://www.w3.org/2000/01/rdf-schema#label |
Firazyr
|
| gptkbp:indication |
hereditary angioedema attacks
|
| gptkbp:ingredients |
icatibant
|
| gptkbp:interacts_with |
none significant reported
|
| gptkbp:is_monitored_by |
monitor for allergic reactions
|
| gptkbp:lifespan |
1.4 hours
|
| gptkbp:manufacturer |
gptkb:Shire_Pharmaceuticals
|
| gptkbp:marketed_as |
gptkb:European_Union
gptkb:United_States |
| gptkbp:metabolism |
primarily hepatic
|
| gptkbp:packaging |
pre-filled syringe
|
| gptkbp:patient_population |
adults with hereditary angioedema
|
| gptkbp:pharmacokinetics |
rapid absorption after injection
blocks bradykinin receptors |
| gptkbp:previous_name |
icatibant
|
| gptkbp:price |
varies by region
|
| gptkbp:provides_guidance_on |
follow prescribing information
recommended for acute attacks |
| gptkbp:regulatory_compliance |
approved in multiple countries
|
| gptkbp:requires |
available online
|
| gptkbp:research |
ongoing for long-term use
|
| gptkbp:route_of_administration |
subcutaneous injection
|
| gptkbp:safety_features |
generally well tolerated
|
| gptkbp:shelf_life |
24 months
|
| gptkbp:side_effect |
headache
nausea abdominal pain diarrhea injection site reactions rarely serious |
| gptkbp:storage |
store in a refrigerator
|
| gptkbp:type_of_care |
important for effectiveness
|
| gptkbp:used_for |
treatment of acute attacks of hereditary angioedema
|
| gptkbp:bfsParent |
gptkb:Cinryze
|
| gptkbp:bfsLayer |
6
|